Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent W Bramwell

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Critical Reviews in Therapeutic Drug Carrier Systems|May 3, 2005
Particulate delivery systems for vaccinesVincent W Bramwell, Yvonne Perrie
Drug Discovery Today|November 1, 2005
The rational design of vaccinesVincent W Bramwell, Yvonne Perrie
The Journal of Pharmacy and Pharmacology|June 1, 2006
Particulate delivery systems for vaccines: what can we expect?Vincent W Bramwell, Yvonne Perrie
Critical Reviews in Therapeutic Drug Carrier Systems|March 29, 2003
Current status of DNA vaccines and their route of administrationH Oya Alpar, Vincent W Bramwell
Expert Opinion on Drug Delivery|November 22, 2005
Strategies for DNA vaccine deliveryH Oya Alpar, Irene Papanicolaou, Vincent W Bramwell
Advanced Drug Delivery Reviews|June 7, 2005
Particulate delivery systems for biodefense subunit vaccinesVincent W Bramwell, Jim E Eyles, H Oya Alpar
Methods (San Diego, Calif.)|January 31, 2006
Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systemsJasvinder Singh, Sreenivas Pandit, Vincent W Bramwell, et al.
Recent Patents on Drug Delivery & Formulation|December 17, 2008
Recent developments in particulate-based vaccinesYvonne Perrie, Daniel Kirby, Vincent W Bramwell, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 29, 2011
Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responsesRandip Kaur, Vincent W Bramwell, Daniel J Kirby, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 18, 2012
Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell responseRandip Kaur, Vincent W Bramwell, Daniel J Kirby, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Critical Reviews in Therapeutic Drug Carrier Systems|May 3, 2005
Particulate delivery systems for vaccinesVincent W Bramwell, Yvonne Perrie
Drug Discovery Today|November 1, 2005
The rational design of vaccinesVincent W Bramwell, Yvonne Perrie
The Journal of Pharmacy and Pharmacology|June 1, 2006
Particulate delivery systems for vaccines: what can we expect?Vincent W Bramwell, Yvonne Perrie
Critical Reviews in Therapeutic Drug Carrier Systems|March 29, 2003
Current status of DNA vaccines and their route of administrationH Oya Alpar, Vincent W Bramwell
Expert Opinion on Drug Delivery|November 22, 2005
Strategies for DNA vaccine deliveryH Oya Alpar, Irene Papanicolaou, Vincent W Bramwell
Advanced Drug Delivery Reviews|June 7, 2005
Particulate delivery systems for biodefense subunit vaccinesVincent W Bramwell, Jim E Eyles, H Oya Alpar
Methods (San Diego, Calif.)|January 31, 2006
Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systemsJasvinder Singh, Sreenivas Pandit, Vincent W Bramwell, et al.
Recent Patents on Drug Delivery & Formulation|December 17, 2008
Recent developments in particulate-based vaccinesYvonne Perrie, Daniel Kirby, Vincent W Bramwell, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 29, 2011
Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responsesRandip Kaur, Vincent W Bramwell, Daniel J Kirby, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 18, 2012
Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell responseRandip Kaur, Vincent W Bramwell, Daniel J Kirby, et al.
Pageof 3